Acute cholestatic hepatitis associated with pravastatin

American Journal of Gastroenterology

Volumn 94, Issue 5, 1999, Pages 1388-1390

  Marek Hartleb, Grzegorz Rymarczyk ^a   Januszewski, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; GROFIBRAT; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CHOLESTATIC HEPATITIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; JAUNDICE; LIVER BIOPSY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ACUTE DISEASE; ANTICHOLESTEREMIC AGENTS; CHOLESTASIS; HEPATITIS, TOXIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIVER; MALE; MIDDLE AGED; PRAVASTATIN;

EID: 0033135964     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1999.01091.x     Document Type: Article

References (10)

1. Ballare M, Campanini M, Aioroldi G, et al. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors. Minerva Gastroenterol Dietol 1992;38:41-4.
2. Catalano PM, Masonson HN, Newman TJ, et al. Clinical safety of pravastatin. In: La Rosa JC, ed. New advances in the control of lipid metabolism. Focus on pravastatin. London: Royal Society of Medicine Services, 1989:35-8.
3. Pan HY. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Pharmacol 1991;40-S15-8.
4. Koornstra JJ, Ottervanger JP, Fehmers MC, et al. Clinically manifest liver lesions during use of simvastatin. Ned Tijdschr Geneeskd 1996;140:846-8.
5. Huchzermeyer H, Miinzenmaier R. Lovastatin-induzierte akute cholestatische Hepatitis. Dtsch Med Wsch 1995;120: 252-6.
6. McQueen M. Cholestatic jaundice associated with lovastatin (Mevacor) therapy. Can Med Assoc J 1990;142:841-2.
7. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28-34.
8. Reydy P, Bogomoletz WV. Un cas d'hepatite a la simvastatine. Gastroenterol Clin Biol 1991;15:94-5.
9. Larrey D, Henrion J, Heller F, et al. Metoprolol-induced hepatitis: Rechallenge and drug oxidation phenotyping. Ann Intern Med 1988;108:67-8.
10. Lennard MS. Metoprolol-induced hepatitis: Is the rate of oxidation related to drug-induced hepatotoxicity? Hepatology 1989;9:163-4.